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ABSTRACT
This report describes the development of a one-tube multiplex reverse transcriptase (RT)-PCR assay for
the simultaneous detection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in
plasma samples. The assay was evaluated with two panels of HCV- and HIV-1-positive samples, as well
as negative plasma specimens. Extraction and amplification of HCV and HIV-1 RNA from plasma
samples were performed in a single reaction, and amplified genomes were detected with specific probes.
Serial dilutions of the HCV and HIV-1 first World Health Organization International Standards were
used to evaluate the sensitivity of the method. Two RNA controls were constructed to determine inter-
assay variations and the sensitivity of the amplification step. The assay had good specificity and
detected all the genotypes and subtypes tested. The analytical sensitivity of the entire assay was
100 IU ⁄mL for HCV and 200 IU ⁄mL for HIV-1, while the amplification step detected ten copies ⁄ reaction
for HCV and 20 copies ⁄ reaction for HIV-1. The multiplex assay allowed the simultaneous extraction,
amplification and detection of two virus genomes, thereby providing an important practical advantage
and an efficient approach for analysing individual and pooled plasma donations.
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INTRODUCTION
Until the 1990s, blood screening and diagnosis
of virus transmission depended entirely on sero-
logical techniques. Despite sensitive antibody-
based blood donor screening, which has greatly
reduced the risk of virus transmission following
blood transfusion, the residual risk for hepatitis C
virus (HCV) and human immunodeficiency virus
type 1 (HIV-1) transmission has been estimated as
1 in 493 000 and 1 in 103 000, respectively, in the
USA and western Europe [1,2]. To reduce this
risk, nucleic acid tests (NATs) for the detection of
HIV-1 and HCV genomes have been developed
over the past decade, combining the advantage of
direct, highly specific detection of infectious
agents with an analytical sensitivity that is several
orders of magnitude higher than that of conven-
tional serological tests [3–5].
Genomic screening for HCV, HIV and hepatitis
B virus (HBV) represents a major step towards
detecting infectious blood collected during the
pre-seroconversion window period, as well as
rare cases of immuno-silent infections and, poss-
ibly, a large spectrum of virus variants. The
results of several studies suggest that the use of
NATs could reduce the window period to
11 days for HCV and HIV, thereby diminishing
further the risk of acquiring infections from
blood transfusions [1,6]. However, a disadvan-
tage is that the cost of NATs is 5–10-fold greater
than that of the most expensive enzyme immu-
noassay. To reduce the cost of NATs, two
approaches have been suggested, namely the
use of pooled plasma testing so that fewer tests
are required to screen large numbers of samples,
and the use of multiplex assays that can detect
several viruses simultaneously.
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Pooling of samples has a relatively small
impact on the ability of a NAT to detect early
infection, as HIV and HCV nucleic acids reach
high levels rapidly after infection is established
[7,8]. The RNA levels can be quantified by means
of target or signal amplification techniques but,
until recently, the quantitative units used in the
various commercial assays did not represent the
same amount of virus RNA in clinical samples.
The World Health Organization (WHO) has now
established an international standard for virus
RNA quantification units. An international unit
(IU) has been defined, arbitrarily but represents
the amount of virus RNA rather than the number
of virus particles in a sample [3]. From July 1999,
regulations issued by the European Committee
for Proprietary Medicinal Products (CPMP ⁄
BWP ⁄ 390 ⁄ 97) have required all plasma pools to
be tested by means of a validated nucleic acid
amplification assay with a sensitivity of at least
100 IU ⁄mL, and to be found negative for HCV [9].
On the basis of data on HCV and HIV RNA levels
during the pre-seroconversion window period,
the USA Food and Drug Administration is likely
to recommend a minimum sensitivity level of
5000 copies ⁄mL for both HIV and HCV at the
individual donation level [10], with a conversion
factor of 1 IU = 3.8 copies for HCV, and
1 IU = 1 copy for HIV [11,12].
The present study investigated the feasibility
and efficacy of a reverse transcriptase (RT)-PCR
assay for the detection of HCV and HIV RNA
simultaneously in plasma samples. The assay was
designed to screen either single or pooled blood
samples. The multiplex format has several advan-
tages in that it reduces the number of processed
samples, the cost of reagents and technician time,
while providing a good safety level for the blood
supply.
MATERIALS AND METHODS
Plasma samples
Clinical sampleswere collected fromblood donors (Blood Bank,
General Hospital, Udine, Italy); because of the difficulty of
obtainingHCV- andHIV-positive donations, volunteer infected
patientswere also recruited.These samples formed threepanels.
Panel A
This comprised 35 samples positive for HCV antibodies (Abs)
and HCV RNA, but HIV-negative. These patients were
screened for HCV Abs with an Ortho HCV v. 3.0 ELISA Test
System (Ortho Clinical Diagnostics, Raritan, NJ, USA), and for
HCV RNA with Cobas Amplicor HCV v. 2.0 (Roche Diagnos-
tics, Indianapolis, IN, USA). Genotyping (for types 1b, 2a, 2a ⁄ c,
3 and 4) was performed with Inno LiPA HCV II (Innogenetics,
Gent, Belgium).
Panel B
This comprised 11 samples obtained from HIV-1 (genotype B)-
infected patients, who were HCV-negative. Patients were
positive when screened for HIV-1 Abs (Sanofi Diagnostics
Pasteur, Marnes-la-Coquette, France) and HIV RNA with
Amplicor HIV (Roche Diagnostics), but negative for both HCV
Abs and HCV RNA.
Panel C
This comprised 70 human plasma samples from frequent
blood donors who were negative for HCV RNA, HIV RNA,
HBV surface antigen, and Abs to HCV and HIV-1, at the time
of enlistment and during the following year. A pool of samples
from this panel was used as a negative control. Whole blood of
samples from panel C was collected in EDTA tubes; plasma
was separated by centrifugation at room temperature, and
then stored at ) 80C and thawed once before use.
The virus load of ten HCV RNA-positive samples from
panel A, and five HIV RNA-positive samples from panel B,
was evaluated with the Quantiplex branched DNA assay
(Chiron Corp., Emeryville, CA, USA). These samples, with
known RNA copy numbers, were diluted in the negative
control to assess the sensitivity of the PCR-based pooling
assay. Aliquots of each sample were then stored at ) 80C and
thawed once before use.
Controls and standards
Validation of test sensitivity was performed for HCV with the
first WHO International Standard code 96 ⁄ 790 (National
Institute of Biological Standards Control (NIBSC), Potters
Bar, UK) containing 100 000 IU ⁄mL, and for HIV-1 with the
NIBSC International Standard code 97 ⁄ 632 containing
50 000 IU ⁄mL. A Working Reagent International Standard
(NIBSC code 97 ⁄ 544) containing HIV-1 genotype B, HCV
genotype 3, hepatitis A virus and parvovirus B19 viral
genomes was also used.
Two RNA controls were used for the determination of inter-
assay variations, caused by the presence of PCR inhibitors.
These HCV andHIV RNA controls were non-infectious in-vitro
synthetic RNAs, transcribed from NIBSC HCV and HIV-1
International Standard target sequences, respectively. A T7
promoter was added upstream of the amplified region, accord-
ing to Fille’s method and the RT-PCR competitor construction
kit protocol (Ambion, Austin, TX, USA) [13]. These control
transcripts were quantified with a RiboGreen RNA Quantifi-
cation Kit (Molecular Probes, Eugene, OR, USA) [14]. Serial
dilutions of control RNA up to the endpoint were used to
determine the analytical sensitivity of the amplification step.
Primer selection
Target RNA sequences were selected within the regions of the
respective virus genomes showing maximum sequence con-
servation; this is critical for the ability of the test to detect all
known genotypes and subtypes of both HCV and HIV [15,16].
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Primer specificity was tested with the Amplify program v. 1.2
[17] against the following genome sequences (available in the
GenBank-EMBL database): HCV complete genome genotypes
1b, 2a, 2b, 2a ⁄ c, 3a, 3b, 4 and 6; HIV-1 complete genome group
M, subtypes A, B, C, E, F1, G, H and I; and the HIV-2 complete
genome. After evaluation of the results of virtual amplification,
different pairs of primers and probes were selected in order to
obtain the most appropriate combination. The primers and
probes selected are shown in Table 1.
Nucleic acid detection
Plasma samples were thawed at room temperature before
extraction. Nucleic acids were extracted from 200 lL of each
sample with the QIAamp virus RNA kit, according to the
instructions of the manufacturer (Qiagen, Hilden, Germany).
Extracted RNAs were reverse-transcribed and amplified in a
single tube with an RT-PCR mix containing the thermostable
rTth polymerase enzyme (PE Applied Biosystems, Norwalk,
CT, USA) and the sense and antisense primers for both HCV
and HIV targets. In brief, 20 lL (30% of the Qiagen eluate)
were added to 30 lL of RT-PCRmix in a single tube containing
1· Buffer EZ (PE Applied Biosystems), 3.3 mMMn acetate (PE
Applied Biosystems), 400 lM dATP, 400 lM dCTP, 400 lM
dGTP, 380 lM dTTP, 20 lM dUTP-Dig (Boehringer, Mannh-
eim, Germany), 0.8 lM primers C1v ⁄C2v, 1.1 lM primers
SK100 ⁄ SK104 (Table 1) and 5 U of rTth. Extracted RNA was
amplified in a single step, with a GeneAmp PCR System 9600
thermal cycler (PE Applied Biosystems). Reverse transcription
was for 30 min at 60C and 2 min at 95C, followed by 40 PCR
cycles of 20 s at 95C and 30 s at 60C for the amplification of
cDNA; after a final extension at 60C for 7 min, the reactions
were held at 4C.
Two aliquots of amplification products were analysed for
the presence of HIV-1 and HCV amplicons, respectively, with
the PCR ELISA DIG Detection Kit (Roche Diagnostics, Monza,
Italy), according to the manufacturer’s instructions, with the
use of 5¢-biotinylated probes (Table 1). Optical density was
measured at 260 nm, with cut-off values calculated from an
analysis of a panel of 50 seronegative plasma samples as the
means of the values plus five standard deviations.
PCR amplicon contamination prevention measures were
strictly applied as described by Kwok and Higushi [18].
RESULTS
RT-PCRs for HCV and HIV-1 were optimised
separately with serial dilutions of NIBSC Interna-
tional Standards (data not shown). The reactions
were combined subsequently to form a multiplex
reaction. Some problems were encountered with a
decrease in sensitivity when the single RT-PCR
reactions were combined. This was corrected by
modifying the RT-PCR mixture; in particular, a
minor modification to the sequence of the HCV
forward primer was necessary to upgrade the
limit of detection and decrease the mismatch
between the two different sets of primers. The
primers and probes were first tested against the
DNA sequences available in the GenBank-EMBL
database, and no interactions were found at this
level. The results suggested that the primers and
probes showed no cross-reactions with human or
virus genomes in a simultaneous amplification.
The final method consisted of RNA extraction,
followed by a single-step reverse transcription
and amplification with an RT-PCR mixture con-
taining both HCV and HIV primers, followed by a
detection step to detect HCV and HIV singly. As
expected, the procedure amplified undiluted
HCV and HIV-1 NIBSC International Standards
successfully (all ten and all eight reactions per-
formed, respectively). No false-positive reactions
were obtained when the analytical specificity of
the procedure was evaluated by testing a panel of
other virus genomes (HBV, cytomegalovirus,
herpes simplex virus, Epstein–Barr virus, parvo-
virus B19).
HCV RNA was detected in all 35 HCV-positive
samples from panel A, and in 15 repeated
samples from the same HCV-positive patients.
HIV RNA was detected in all 11 HIV-positive
samples from panel B, and in nine repeated
samples from the same HIV-positive patients.
None of the 70 samples from panel C was positive
for HCV or HIV RNA.
The plasma samples tested were from seropos-
itive patients infected with HCV genotypes 1b, 2a,
2b, 2a ⁄ c, 3a, 3b and 6a, or with HIV-1 subtype
B. All of these were positive in the assay. The
assay was also able to detect HCV and HIV RNA
simultaneously in the same sample when tested
Table 1. Primers and probes used
for detection of HCV and HIV RNA Virus
Primers
or probes [Ref.] Sequence (5¢)3¢)
Virus
genome Usage
HCV C1v ATCACTCCCCTGTGAGGAAC 35–54 Reverse primer
HCV C2v CCCAACACTACTCGGCTA 268–251 Forward primer
HCV P6 [15] Biotin-GCCATGGCGTTAGTATGAGTGTC 81–103 Probe
HIV-1 SK100 [16] ATCAAGCAGCCATGCAAAT 916–934 Reverse primer
HIV-2 1132–1150
HIV-1 SK104 [16] CTTTTGGTCCTTGTCTTATGTC 1185–1206 Forward primer
HIV-2 1401–1422
HIV-1 H-1 probe Biotin-AATGAGGAGGCTGCAGAATGGGA 951–973 Probe
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against the NIBSC Working Reagent International
Standard code 97 ⁄ 544 (containing HIV-1 geno-
type B, HCV genotype 3, hepatitis A virus and
parvovirus B19 viral genomes).
The sensitivity of the entire procedure was
determined with the HCV and HIV-1 WHO
International Standards. The endpoint titration
was arrived at by mixing NIBSC International
Standards in negative controls (Table 2). The
detection limit of the test was defined as the
concentration required to yield positive results in
at least 95% of replicate reactions. The detection
limit of the multiplex RT-PCR was 100 IU ⁄mL for
the HCV WHO International Standard, and
200 IU ⁄mL for the HIV-1 WHO International
Standard.
Five replicate extractions were performed for
each diluted sample, and a single amplification
was performed for each extract. The analytical
sensitivity of the amplification step (amplification
and detection only) was evaluated by direct
amplification of HCV and HIV RNA controls,
diluted as shown in Table 3. Ten copies of HCV
and 20 copies of the HIV RNA control, respect-
ively, gave positive results in 96.6% of reactions.
A small difference in sensitivity was observed on
comparison of the analytical sensitivities of the
entire procedure and the amplification and detec-
tion steps only.
For assessment of the clinical sensitivity of the
assay, ten samples positive for HCV RNA from
panel A and five samples positive for HIV RNA
from panel B, with known RNA genome equiv-
alent numbers, were diluted in negative control
plasma and replicate assays were performed.
Positive results were obtained (‡ 95% of repli-
cates) with 500–1000 genome equivalents ⁄mL for
HCV, and with 1000 genome equivalents ⁄mL for
HIV (Table 4). These results were consistent with
the NIBSC finding that one IU is equivalent to
about four genome equivalents for HCV [19].
The reproducibility of the sample preparation
method was determined with the standard
specimen processing conditions, including sam-
ple handling and storage conditions. The assay
precision was established by performing multiple
tests with multiple operators, with different lots
of reagents, on a panel of specimens. Thus the
intra-assay reproducibility of the method was
determined by testing, on six occasions, a panel of
four HCV RNA-positive and four HIV RNA-
positive samples, as well as four negative samples
for both targets, with three different operators on
three different days. Identical results were
obtained in all instances.
DISCUSSION
The risk of transfusion-transmitted virus infec-
tions is primarily a result of the failure of
serological screening tests of pooled sera to detect
recently infected donors in the pre-seroconversion
window period of infection [20,21]. To reduce this
Table 2. Analytical sensitivity of the entire procedure
(extraction ⁄ amplification ⁄detection), as evaluated with
the use of limiting dilutions of NIBSC International
Standards
HCV International Standard HIV-1 International Standard
IU/mL Replicates Positive IU/mL Replicates Positive
5000 10 10 ⁄ 10 5000 10 10 ⁄ 10
1000 10 10 ⁄ 10 1000 10 10 ⁄ 10
500 10 10 ⁄ 10 500 10 10 ⁄ 10
200 30 30 ⁄ 30 200 45 43 ⁄ 45
100 45 43 ⁄ 45 100 45 41 ⁄ 45
75 40 36 ⁄ 40 75 30 26 ⁄ 30
50 20 11 ⁄ 20 50 20 9 ⁄ 20
10 10 2 ⁄ 10 10 10 1 ⁄ 10
5 10 0 ⁄ 10 5 10 0 ⁄ 10
0 10 0 ⁄ 10 0 10 0 ⁄ 10
NIBSC, National Institute of Biological Standards Control.
Table 3. Analytical sensitivity of the amplification step
(amplification ⁄detection) evaluated with the use of limit-
ing dilutions of RNA controls
HCV RNA control HIV 1 RNA control
Copies/PCR Replicates Positive Copies/PCR Replicates Positive
5000 10 10 ⁄ 10 5000 10 10 ⁄ 10
1000 10 10 ⁄ 10 1000 10 10 ⁄ 10
500 10 10 ⁄ 10 500 10 10 ⁄ 10
100 10 10 ⁄ 10 100 10 10 ⁄ 10
50 20 20 ⁄ 20 50 20 20 ⁄ 20
20 30 30 ⁄ 30 20 30 29 ⁄ 30
10 30 29 ⁄ 30 10 30 27 ⁄ 30
5 20 16 ⁄ 20 5 20 13 ⁄ 20
0 10 0 ⁄ 10 0 10 0 ⁄ 10
Table 4. Positive detection rate for diluted clinical sam-
ples
HCV HIV
geq/mL Replicates Positive geq/mL Replicates Positive
5000 20 20 ⁄ 20 5000 20 20 ⁄ 20
1000 25 25 ⁄ 25 1000 25 24 ⁄ 25
500 25 23 ⁄ 25 500 25 19 ⁄ 25
100 25 18 ⁄ 25 100 25 11 ⁄ 25
50 25 10 ⁄ 25 50 25 6 ⁄ 25
10 20 0 ⁄ 20 10 20 0 ⁄ 20
geq, genome equivalents.
1078 Clinical Microbiology and Infection, Volume 10 Number 12, December 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 1075–1080
period, Paul Ehrlich Institute (Langen, Germany)
regulations stipulate that at least 5000 IU ⁄mL
must be detected to calculate the amount contri-
buted by individual donations comprising the
pool [22]. NAT screening of pooled sera will
result in positive reactions with a frequency that
depends on the incidence of virus infections in the
donor population and the sensitivity of the test
method used [1,9]. This statement was a major
impetus for developing and implementing NAT
of blood and plasma from blood donors.
This report describes the development of a
qualitative RT-PCR-based assay for the simulta-
neous extraction, amplification and detection of
HCV and HIV RNA in plasma samples. The aims
were to select target RNA sequences for HCV and
HIV in genome regions that show maximum
sequence conservation, and to obtain primers and
probes capable of detecting simultaneously all
genotypes and subtypes of both HCV and HIV.
The optimisation of the multiplex RT-PCR
amplification focused initially on the compatibil-
ity of the primer pairs during the RT-PCR
amplification in order to avoid potential interac-
tions among primers and between primer and
amplicon [23]. A decrease in sensitivity observed
when the single RT-PCR reactions were combined
was corrected by modifying the RT-PCR mixture
to upgrade the limit of detection and decrease the
mismatch between the sets of primers. The
RT-PCR system was also tested for possible non-
specific reactions, but no false-positive reactions
were detected with human or a range of virus
genomes in a simultaneous amplification.
The assay had an analytical sensitivity of
approximately 100 IU and 200 IU ⁄mL of plasma
for HCV and HIV-1, respectively, which are
values well-suited for screening blood samples.
This analytical sensitivity is below that required
by European guidelines for blood safety [24], but
it could be improved further by using more
cumbersome and time-consuming techniques
(e.g., ultracentrifugation) for extraction and ⁄ or
detection. A small difference in sensitivity was
observed between the entire procedure and the
amplification ⁄detection steps only, perhaps
resulting from the different nature of the sample
or from the loss of virus genomes during the
extraction step. The use of International Stand-
ards from NIBSC will allow more valid compar-
isons with other NAT systems and NAT
laboratories.
The easy-handling and manual features of the
method could be an advantage for those laborat-
ories processing low numbers of samples. How-
ever, the method could be automated easily, and
the amplification step could be combined with
any commercially available RNA extraction and
detection kit in order to enable assay of a variable
number of samples. The procedure is already
suitable for the concomitant detection of HIV-1
and HIV-2 to meet the growing needs for NAT
screening in blood units [25,26], and should also
be feasible for screening stem cells before release
for transplantation [27,28]. Future efforts should
be directed to large-scale screening of such sam-
ples, as well as to the development of new
multiplex PCR-based tests for other transfusion-
associated agents.
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